



Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01625K	APPLICATION NO.: 10/665,005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Kamil Paruch et al.	
				FILING DATE: 09/19/2003	GROUP: 1624
U. S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
AA					SUB-CLASS
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					
AK					
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
					SUB-CLASS
DR ✓	AL	EP 0 778 277	06/11/1997	EPO	
DR ✓	AM	WO 02/06286	01/24/2002	PCT	
DR ✓	AN	WO 88/04298	06/16/1988	PCT	
	AO				
	AP				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
DR	AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224 : 771-786.			
DR	AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients With Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16 (9): 2986-2999.			
DR	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243 : 527-536.			
DR	AT	Bible et al., "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57 : 3375-3380.			
DR	AU	Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5 α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47 (7): 928-938.			
DR	AV	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10 : 620-626.			
EXAMINER		DATE CONSIDERED			
<i>Dnyak</i>		<i>3/10/04</i>			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.